Goldfarb Branham LLP is investigating Micrus Endovascular’s Board of Directors (NASDAQ: MEND) due to the recent merger they approved with Johnson & Johnson for a 5.5% premium. Micrus shareholders are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or by email hlindley@goldfarbbranham.com for details about their rights.

“If the transaction closes, Micrus investors will be cashed out at $23.40 per share,” stated shareholder lawyer Hamilton Lindley. “Micrus may not have adequately shopped itself before entering into this transaction, and Johnson & Johnson may be underpaying for Micrus, thus unlawfully harming Micrus shareholders.”

If you own Micrus stock and you wish to discuss this matter with an experienced shareholder attorney, please contact Hamilton Lindley at 877-583-2855 or by email at hlindley@goldfarbbranham.com. Goldfarb Branham LLP lawyers have excellent experience representing shareholders in buyout cases nationwide. The firm provides nimble, creative and effective counsel at all stages of litigation.

Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Gen 2025 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)
Grafico Azioni Micrus Endovascular (MM) (NASDAQ:MEND)
Storico
Da Feb 2024 a Feb 2025 Clicca qui per i Grafici di Micrus Endovascular (MM)